StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 
 
 
Novavax
5.29
+8.40%
 

NVAX

 

Novavax

$ 5.29

 
+$0.41 | +8.40%
 
 
Open
$ 5.06
 
 
MKT CAP
$ 628.40M
 
High
$ 5.46
 
 
VOL
$ 18.33M
 
Low
$ 4.91
 
 
AVG VOL
$ 7.63M
 
 
 

NVAX Stock Analysis

  Login to display Novavax (NVAX) recommendation from the last 90 days from financial news and social media.
 
 

NVAX Total Score

 

Chart

 
 

4.56

5.57

7.45

6.86

 
 
1month
3month
6month
1year
 
Total Return
NVAX
vs.
S&P500
 

 
1-week Return
+23.02%
 
+1.17%
 
 
5-week Return
+28.71%
 
+6.44%
 
 
10-week Return
-5.03%
 
+10.09%
 
 
 
 
 

NVAX Risk Level

This Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
NVAX Risk Level
LOW
HIGH

Risk Volatility

 

NVAX has High Risk Level

Click here to check what is your level of risk

 

NVAX Analysts Opinion

The company overall standing based on key factors, offering insights into analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

NVAX Earnings Sentiment

 Above analyst estimates

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.25
 

NVAX Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.80
 
 

Future

×
 

Future

2.50
 
 
 

NVAX Analysts Opinion

NVAX Analysts opinion is negative and it remained unchanged from the past 3 months

 

NVAX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
76%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
63%
50%
 
On Track
On Track
On Track
 

NVAX Street Opinion 

NVAX Street view is extremely ish but have mixed views on the near-term outlook

 

NVAX Performance Sentiment

Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
76%
24%
Positive
Negative
16 out of 21
events present
5 out of 21
events present
 
 

NVAX Earnings

The Trailing Twelve Months (TTM) reflects 12-month period, providing rview of NVAX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
974
1,982
1,146
-7.81%
 
 
Cost of Revenue
371
903
-
 
 
Gross Profit
603
1,079
1,146
-27.46%
 
 
Operating Expense
1,230
1,724
2,833
-34.11%
 
 
Operating Income
-627
-645
-1,687
-
 
 
Net Interest Income
-15
-20
-21
-
 
 
Interest Expense
15
20
21
-15.48%
 
 
Other Income
91
11
-7
-
 
 
EPS
-6.23
-8.42
-23.44
-
 
 
Next Earnings Date: Feb 26, 2024
 
Similar to NVAX
Total Score
Close Price
%
Change

MRNA

Moderna

3.62

96.46

-3.00%

 
 
 
Highlights
Last Modify
Price
% Change

 
Agreements
This Week
4.88
+22.61%
 
Cut Workforce
3 Weeks Ago
4.00
-0.74%
 
Investors Activity
2 Month Ago
4.81
-6.60%
 
 

NVAX Latest News Feed




















 
 
 
joker
 
 
 
StocksRunner

Explore our NVAX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our NVAX Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 

Most Trending

 
 

-2.76%

 
 
 
 
 
 
 
 
 

Stock Insights

 
 
 

Not Enough Information

 
 
 

NVAX Risk Level

 
 
 

The Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
NVAX Risk Level
LOW
HIGH

Risk Volatility

 

NVAX has High Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

NVAX

 

Novavax

$ 5.29

 
+$0.41 | +8.40%
 
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 5.06
 
 
MKT CAP
$ 628.40M
 
High
$ 5.46
 
 
VOL
$ 18.33M
 
Low
$ 4.91
 
 
AVG VOL
$ 7.63M
 
 
 

NVAX Analysis

  Sign in to view Novavax (NVAX) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

4.56

5.57

7.45

6.86

 
 
1month
3month
6month
1year
 
Total Return
NVAX
vs.
S&P500
 

 
1-week Return
+23.02%
 
+1.17%
 
 
5-week Return
+28.71%
 
+6.44%
 
 
10-week Return
-5.03%
 
+10.09%
 
 
 

NVAX Analysts Opinion

Overall standing by considering key factors, reflecting analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

NVAX Earnings Sentiment

 Above analyst estimates

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.25
 

NVAX Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.80
 
 

Future

×
 

Future

2.50
 
 
 

NVAX Analysts Opinion

NVAX Analysts opinion is negative and it remained unchanged from the past 3 months

 

NVAX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
76%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
63%
50%
 
On Track
On Track
On Track
 

NVAX Street Opinion 

NVAX Street view is extremely ish but have mixed views on the near-term outlook

 
NVAX Performance Sentiment
Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
76%
24%
Positive
Negative
16 out of 21
events present
5 out of 21
events present
 

 

NVAX Earnings

The Trailing Twelve Months (TTM) data reflects the most recent 12-month period, providing overview of NVAX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
974
1,982
1,146
-7.81%
 
 
Cost of Revenue
371
903
-
 
 
Gross Profit
603
1,079
1,146
-27.46%
 
 
Operating Expense
1,230
1,724
2,833
-34.11%
 
 
Operating Income
-627
-645
-1,687
-
 
 
Net Interest Income
-15
-20
-21
-
 
 
Interest Expense
15
20
21
-15.48%
 
 
Other Income
91
11
-7
-
 
 
EPS
-6.23
-8.42
-23.44
-
 
 
Next Earnings Date: Feb 26, 2024
 
Highlights
Last Modify
Price
% Change

 
Agreements
This Week
4.88
+22.61%
 
Cut Workforce
3 Weeks Ago
4.00
-0.74%
 
Investors Activity
2 Month Ago
4.81
-6.60%
 
 
NVAX Latest News Feed

Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.

Fri Feb 23, 2024

Momentum

Novavax nears five-month high as COVID vaccine dispute ends.

Thu Feb 22, 2024

Momentum

NICE Posts Upbeat Earnings Joins FTI Consulting NVIDIA Moderna And Other Big Stocks Moving Higher On Thursday. United States stocks were higher with the Nasdaq Composite gaining more 2% on Thursday. Shares of ) rose sharply during Thursday&rsquo.s sessio

Thu Feb 22, 2024

Activity
Earnings

Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase. The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

Thu Feb 22, 2024

Momentum

Novavax to settle Gavi arbitration over canceled Covid shot purchase. A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21 2022 in The Hague Netherlands. Sh

Thu Feb 22, 2024

Momentum

Novavax settles dispute with international vaccine group Gavi. Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028 settling a dispute over canceled orde

Thu Feb 22, 2024

Potential

Novavax to settle dispute over canceled Covid vaccine purchase agreement. A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21 2022 in The Hague Netherlands

Thu Feb 22, 2024

Activity

Novavax Gavi Settle Pending Arbitration Related To Vaccine Advance Purchase Agreement. (RTTNews) - Novavax Inc. (NVAX) and Gavi the Vaccine Alliance have reached a settlement related to the 2021 Advance Purchase Agreement for Novavaxs prototype

Thu Feb 22, 2024

Activity

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement. GAITHERSBURG Md. and GENEVA Feb. 22 2024 /PRNewswire/ -- Novavax Inc. (Nasdaq: NVAX) and Gavi the Vaccine Alliance (Gavi) today announced they have reached a settlement

Thu Feb 22, 2024

Activity

novavaxs malaria vaccine gets who prequalification has potential of being an affordable option. novavax inc nvax announced that peer-reviewed results from a phase 3 efficacy trial of the r21/matrix-m malaria vaccine were published in the lancet on friday.

Fri Feb 2, 2024

Potential

novavax-backed malaria vaccine shows 75% efficacy.

Fri Feb 2, 2024

Activity

looking into novavaxs recent short interest. ) short percent of float has risen 3.5% since its last report. the company recently reported that it has

Wed Jan 31, 2024

Activity

novavax to cut 12% of global workforce amid restructuring drive.

Wed Jan 31, 2024

Activity

novavax to cut 12% of its global workforce. vaccine maker novavax said on wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.

Wed Jan 31, 2024

Activity

novavax announces fresh round of layoffs to rein in costs.

Wed Jan 31, 2024

Activity

1 reason to buy novavax stock and 3 (better) reasons to sell. like many of the biotechs pursuing coronavirus vaccine development novavax (nasdaq: nvax) has seen better days. its shares are down by 96% over the past three years and the companys r

Mon Jan 29, 2024

Momentum

1 reason to buy novavax stock hand over fist and 1 reason to sell. novavax (nasdaq: nvax) shares have offered investors a roller coaster ride over the past few years. they soared more than 2700% in early pandemic days as investors bet on the company'.s

Mon Jan 29, 2024

Momentum

novavax inc. (nvax) ceo john jacobs presents at jpmorgan 42nd annual healthcare conference transcript.

Tue Jan 9, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 21 events in the last 90 days from financial news and social media. Last updated Feb 23, 2024 13:28 Wall St. time
 
 

NVAX Total Score

 
 
 
 
 

Similar to NVAX

 
 
 
Symbol
Score
% Change

MRNA

Moderna

3.62

-3.00%

96.46

 
 
 
 
 
 
StocksRunner

Discover NVAX Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of NVAX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our NVAX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVAX Stock trends

NVAX Stock performance

NVAX Stock analysis

NVAX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker